Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis.

Yamada K, Noguchi K, Kimitsuki K, Kaimori R, Saito N, Komeno T, Nakajima N, Furuta Y, Nishizono A.

Antiviral Res. 2019 Dec;172:104641. doi: 10.1016/j.antiviral.2019.104641. Epub 2019 Oct 28.

PMID:
31672666
2.

Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice.

Westover JB, Hickerson BT, Van Wettere AJ, Hurst BL, Kurz JP, Dagley A, Wülfroth P, Komeno T, Furuta Y, Steiner T, Gowen BB.

Pathogens. 2019 Sep 21;8(4). pii: E158. doi: 10.3390/pathogens8040158.

3.

Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration.

Tani H, Komeno T, Fukuma A, Fukushi S, Taniguchi S, Shimojima M, Uda A, Morikawa S, Nakajima N, Furuta Y, Saijo M.

PLoS One. 2018 Oct 26;13(10):e0206416. doi: 10.1371/journal.pone.0206416. eCollection 2018.

4.

Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice.

Hawman DW, Haddock E, Meade-White K, Williamson B, Hanley PW, Rosenke K, Komeno T, Furuta Y, Gowen BB, Feldmann H.

Antiviral Res. 2018 Sep;157:18-26. doi: 10.1016/j.antiviral.2018.06.013. Epub 2018 Jun 21.

PMID:
29936152
5.

Use of Favipiravir to Treat Lassa Virus Infection in Macaques.

Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro C, Feldmann F, Saturday G, Lovaglio J, Scott DP, Furuta Y, Komeno T, Gowen BB, Safronetz D.

Emerg Infect Dis. 2018 Sep;24(9):1696-1699. doi: 10.3201/eid2409.180233. Epub 2018 Sep 17.

6.

Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN.

Sci Rep. 2018 May 15;8(1):7604. doi: 10.1038/s41598-018-25780-3.

7.

Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients.

Hickerson BT, Westover JB, Jung KH, Komeno T, Furuta Y, Gowen BB.

J Infect Dis. 2018 Jul 13;218(4):522-527. doi: 10.1093/infdis/jiy159.

8.

Heartland virus infection in hamsters deficient in type I interferon signaling: Protracted disease course ameliorated by favipiravir.

Westover JB, Rigas JD, Van Wettere AJ, Li R, Hickerson BT, Jung KH, Miao J, Reynolds ES, Conrad BL, Nielson S, Furuta Y, Thangamani S, Wang Z, Gowen BB.

Virology. 2017 Nov;511:175-183. doi: 10.1016/j.virol.2017.08.004. Epub 2017 Aug 31.

9.

Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy.

Gowen BB, Westover JB, Sefing EJ, Van Wettere AJ, Bailey KW, Wandersee L, Komeno T, Furuta Y.

Antiviral Res. 2017 Sep;145:131-135. doi: 10.1016/j.antiviral.2017.07.019. Epub 2017 Aug 2.

10.

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.

Furuta Y, Komeno T, Nakamura T.

Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027. Review.

11.

Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir.

Gowen BB, Westover JB, Miao J, Van Wettere AJ, Rigas JD, Hickerson BT, Jung KH, Li R, Conrad BL, Nielson S, Furuta Y, Wang Z.

J Virol. 2017 Jan 18;91(3). pii: e01942-16. doi: 10.1128/JVI.01942-16. Print 2017 Feb 1.

12.

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.

Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T.

Antiviral Res. 2016 Aug;132:170-7. doi: 10.1016/j.antiviral.2016.06.007. Epub 2016 Jun 16.

13.

Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.

Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB.

Antiviral Res. 2016 Feb;126:62-8. doi: 10.1016/j.antiviral.2015.12.006. Epub 2015 Dec 19.

14.

Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.

Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A.

J Infect Dis. 2016 Apr 15;213(8):1253-61. doi: 10.1093/infdis/jiv586. Epub 2015 Dec 9.

15.

The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.

Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB.

Sci Rep. 2015 Oct 12;5:14775. doi: 10.1038/srep14775.

16.

Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.

Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, Hall JO.

Antiviral Res. 2015 Sep;121:132-7. doi: 10.1016/j.antiviral.2015.07.003. Epub 2015 Jul 14.

17.
18.

Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.

Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB.

Antiviral Res. 2014 Apr;104:84-92. doi: 10.1016/j.antiviral.2014.01.016. Epub 2014 Jan 31.

19.

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever.

Gowen BB, Juelich TL, Sefing EJ, Brasel T, Smith JK, Zhang L, Tigabu B, Hill TE, Yun T, Pietzsch C, Furuta Y, Freiberg AN.

PLoS Negl Trop Dis. 2013 Dec 26;7(12):e2614. doi: 10.1371/journal.pntd.0002614. eCollection 2013.

20.

In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.

Tarbet EB, Vollmer AH, Hurst BL, Barnard DL, Furuta Y, Smee DF.

Arch Virol. 2014 Jun;159(6):1279-91. doi: 10.1007/s00705-013-1922-1. Epub 2013 Dec 6.

PMID:
24311151

Supplemental Content

Loading ...
Support Center